RecruitingNot ApplicableNCT03932903

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

Using Real Time Mobile Health Approaches to Understand and Promote Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

Sponsor

Northwestern University

Enrollment

60 participants

Start Date

Jul 31, 2025

Study Type

INTERVENTIONAL

Conditions

Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma

Summary

This is a small-scale micro-randomized clinical trial of a new mobile just-in-time adaptive intervention (JITAI) designed to promote oral chemotherapy adherence in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL). The goals of this study are to determine intervention feasibility and acceptability.

Eligibility

Min Age: 14 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a mobile phone app can help teenagers and young adults with leukemia take their oral chemotherapy (6-mercaptopurine) more consistently during the long-term maintenance phase of treatment. **You may be eligible if...** - You are between 14 and 29 years old - You have been diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma and are in the maintenance phase with at least one month of treatment remaining - You are prescribed 6-mercaptopurine and can speak and read English - If you are under 18, a caregiver must provide consent on your behalf **You may NOT be eligible if...** - You have cognitive impairments that would prevent you from completing study tasks, as determined by your medical team Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALADAPTS (ADherence Assessments and Personalized Timely Support).

ADAPTS is a mobile app intervention that integrates contextually-tailored mobile messages and decision rules about when to deliver the messages, with the ultimate goal of improving oral chemotherapy adherence in AYAs with acute lymphoblastic leukemia and lymphoma. AYA participants will be micro-randomized to receive messages on some days that are adapted to their current characteristics (e.g., mood, pain, location) and designed to promote adherence, and no messages (no intervention) on other days. Other features in the app include a medication calendar that syncs with the electronic medication monitor (eCAP) to track daily adherence. A caregiver version of ADAPTS is also available, providing daily surveys (but no randomized mobile messages) and the medication calendar so that dyads can mutually track adherence.

Locations(1)

Robert H. Lurie Comprehensive Cancer Center, Northwestern University

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03932903

Related Trials

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

NCT062896733 locations

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

NCT065337482 locations

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

NCT061958911 location

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT067356901 location

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

NCT072287411 location